Fatalities from Tumor Lysis Syndrome (TLS) After Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol
Author Type(s)
Faculty
Document Type
Abstract
Publication Date
10-2022
Journal Title
Clinical Lymphoma Myeloma & Leukemia
Department
Pediatrics
Recommended Citation
Cairo, M. S., Gallagher, J. R., Barnes, Y., Drea, E., & Carrol, S. (2022). Fatalities from Tumor Lysis Syndrome (TLS) After Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol. Clinical Lymphoma Myeloma & Leukemia, 22, S302-S303. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/760
COinS